Last reviewed · How we verify
NCT06178042
Effectiveness of MI Paste Plus and Remin Pro on Remineralization of Post-Orthodontic White Spot Lesions
NA trial testing MI Paste Plus in White Spot Lesion in 39 participants. Completed in 25 May 2022.
1 February 2022
Quick facts
| Lead sponsor | Izmir Katip Celebi University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 39 |
| Start date | 1 February 2020 |
| Primary completion | 1 February 2022 |
| Estimated completion | 25 May 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- MI Paste Plus — full drug profile →
- Remin Pro
- Control
Conditions studied
- White Spot Lesion — all drugs for White Spot Lesion →
- Remineralization — all drugs for Remineralization →
Sponsor
Izmir Katip Celebi University
Who can join
Adults 12 to 25, any sex, with White Spot Lesion or Remineralization. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
One of the most undesired side effects of fixed orthodontic treatment is white spot lesions (WSLs), that appear on the buccal surface of teeth and cause aesthetic problems. The aim of this prospective study was to quantitively evaluate the remineralization effect of casein phosphopeptide-amorphous calcium fluorophosphate (CPP-ACFP) containing (MI Paste Plus®) and hydroxyapatite, xylitol and fluoride containing (Remin Pro®) agents in remineralizing post orthodontics white spots using Quantitive Light-Induced Fluorescence Method (QLF) and ICDAS II criteria, compared to a control group in whom just a routine home care was instructed. Thirty-nine individuals who had recently completed orthodontic treatment, had at least one WSL on upper anterior teeth and aged between 12-25 years were included. The participants were randomly assigned into three groups of 13 each; (1) MI Paste Plus + routine home care; (2) Remin Pro + routine home care; and (3) routine home care (control). The treatment/ observation period was 12 weeks after bracket debonding. Fluorescence loss (∆F, %), lesion area (LA, mm2), lesion volume (∆Q, % × mm2), maximum fluorescence loss (∆Fmax), ICDAS II criteria of WSLs were measured at beginning (T0) and 4 (T1), 8 (T2), and 12 (T3) weeks later. Statistical significance was set at p\<0.05.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06178042
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for White Spot Lesion
Currently open trials in the same condition.
- NCT07319884 — The Role of Fluoride Varnish Application in Preventing White Spot Lesions During Clear Aligner Treatment: A Controlled S · NA · active not recruiting
Other Izmir Katip Celebi University trials
Trials by the same sponsor.
- NCT07460479 — Pilot Study of an Extended CBT Group Intervention for Intolerance of Uncertainty · NA · recruiting
- NCT07453277 — Blood-Based Molecular Clock Biomarkers Predict Acute Ischemic Stroke Onset: A Prospective Observational Study · active not recruiting
- NCT07341646 — Effect of Cuff Pressure Assessment Methods on Postoperative Complications in Breast Surgery · NA · not yet recruiting
- NCT07304661 — Comparison of PPV and LVOT VTI During Passive Leg Raising to Predict Fluid Responsiveness · not yet recruiting
- NCT07304648 — Role of End-Tidal CO2 During Passive Leg Raising to Predict Fluid Responsiveness in ICU · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06178042 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Izmir Katip Celebi University
- Last refreshed: 20 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06178042.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing